Phreesia, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Vruwink from Robert W. Baird downgraded the rating on the stock to a Hold and gave it a $10.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Joseph Vruwink has given his Hold rating due to a combination of factors tied to Phreesia’s near‑term growth and end‑market dynamics. While the company continues to post solid margin expansion and materially improved free cash flow, its FY27 revenue forecast was cut as pharmaceutical brands reduced marketing commitments to the Network Solutions segment, introducing more uncertainty into the growth profile despite management’s view that these pressures are not structural.
At the same time, the shares already trade at what appears to be a low multiple on EBITDA and free cash flow, which limits downside purely from valuation compression and reflects some of the slowdown risk. Vruwink also acknowledges potential upside if Phreesia can contain the weakness to a few categories, execute on initiatives like AccessOne and HCP marketing, and demonstrate steadier estimates, but he sees the combination of decelerating growth and negative revisions as limiting the conviction needed for a more positive rating at this stage.
In another report released today, Citi also downgraded the stock to a Hold with a $10.00 price target.
Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHR in relation to earlier this year.